相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
Matthew J. Budoff et al.
CARDIOVASCULAR RESEARCH (2021)
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction A Randomized, Controlled Trial
Are Annesonn Kalstad et al.
CIRCULATION (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
REDUCE-IT USA Results From the 3146 Patients Randomized in the United States
Deepak L. Bhatt et al.
CIRCULATION (2020)
Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review
Daniel E. Hilleman et al.
ADVANCES IN THERAPY (2020)
Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association
Salim S. Virani et al.
CIRCULATION (2020)
Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2020 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2020)
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
R. Preston Mason et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults
Zhi-Hong Yang et al.
NUTRIENTS (2020)
COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS
William S. Weintraub et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes The ODYSSEY OUTCOMES Trial
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
Matthew J. Budoff et al.
EUROPEAN HEART JOURNAL (2020)
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk The STRENGTH Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial: Insight From the Veterans Affairs Healthcare System
Xiaoming Jia et al.
CIRCULATION (2019)
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
Fabien Picard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Residual Cardiovascular Risk in Statin-Treated Patients with Elevated Triglycerides: Now We Can REDUCE-IT!
Deepak L. Bhatt
EUROPEAN HEART JOURNAL (2019)
The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy
Brian C. Case et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
Ann C. Skulas-Ray et al.
CIRCULATION (2019)
Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Cardiovascular risk reduction with icosapent ethyl
Parth N. Patel et al.
CURRENT OPINION IN CARDIOLOGY (2019)
National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
Carl E. Orringer et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
FISHing for the Miracle of Eicosapentaenoic Acid
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
JoAnn E. Manson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
Matthew Budoff et al.
CLINICAL CARDIOLOGY (2018)
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Om P. Ganda et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
The Burden of Cardiovascular Diseases Among US States, 1990-2016
Gregory A. Roth et al.
JAMA CARDIOLOGY (2018)
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks Meta-analysis of 10 Trials Involving 77 917 Individuals
Theingi Aung et al.
JAMA CARDIOLOGY (2018)
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Stephen J. Nicholls et al.
CLINICAL CARDIOLOGY (2018)
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus
Louise Bowman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
Aruna D. Pradhan et al.
AMERICAN HEART JOURNAL (2018)
A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins
Tetsu Watanabe et al.
JOURNAL OF CARDIOLOGY (2017)
A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk
Dominik D. Alexander et al.
MAYO CLINIC PROCEEDINGS (2017)
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
John R. Nelson et al.
POSTGRADUATE MEDICINE (2017)
Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits
R. Preston Mason et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
Deepak L. Bhatt et al.
CLINICAL CARDIOLOGY (2017)
Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
Jonathan Fialkow
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2016)
Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story
Sarabjeet Singh et al.
AMERICAN JOURNAL OF THERAPEUTICS (2016)
Do Genetic Factors Modify the Relationship Between Obesity and Hypertriglyceridemia?: Findings From the GLACIER and the MDC Studies
Ashfaq Ali et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2016)
The Supplement Paradox Negligible Benefits, Robust Consumption
Pieter A. Cohen
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Trends in Dietary Supplement Use Among US Adults From 1999-2012
Elizabeth D. Kantor et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial
Ivor B. Asztalos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Do Genetic Factors Modify the Relationship Between Obesity and Hypertriglyceridemia?: Findings From the GLACIER and the MDC Studies
Ashfaq Ali et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2016)
Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011
Dima M. Qato et al.
JAMA INTERNAL MEDICINE (2016)
Interactions of Lipid Genetic Risk Scores With Estimates of Metabolic Health in a Danish Population
Johanne M. Justesen et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Emergency Department Visits for Adverse Events Related to Dietary Supplements
Andrew I. Geller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Interactions of Lipid Genetic Risk Scores With Estimates of Metabolic Health in a Danish Population
Johanne M. Justesen et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States
Alison C. Kleiner et al.
JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE (2015)
Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA
Benjamin B. Albert et al.
SCIENTIFIC REPORTS (2015)
Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety
Stefan A. Jackowski et al.
JOURNAL OF NUTRITIONAL SCIENCE (2015)
Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-Rationale and design
Tetsu Watanabe et al.
JOURNAL OF CARDIOLOGY (2014)
Hazards of Hindsight - Monitoring the Safety of Nutritional Supplements
Pieter A. Cohen
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study
Kristian Laake et al.
BMC GERIATRICS (2014)
Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
Harold E. Bays et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2013)
Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
Anders Berg Jorgensen et al.
EUROPEAN HEART JOURNAL (2013)
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Anette Varbo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Quality analysis of commercial fish oil preparations
Jenna C. Sullivan Ritter et al.
JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE (2013)
The Eicosapentaenoic Acid Metabolite 15-Deoxy-δ-Prostaglandin J3 Increases Adiponectin Secretion by Adipocytes Partly via a PPARγ-Dependent Mechanism
Jennifer Lefils-Lacourtablaise et al.
PLOS ONE (2013)
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
Christie M. Ballantyne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
α-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis
An Pan et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2012)
The Change in Low-Density Lipoprotein Cholesterol Concentration is Positively Related to Plasma Docosahexaenoic Acid but not Eicosapentaenoic Acid
Hiroshige Itakura et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2012)
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other Lipids: A review
Terry A. Jacobson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2012)
Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)
Harold E. Bays et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis
Melissa Y. Wei et al.
CURRENT ATHEROSCLEROSIS REPORTS (2011)
Fatty acid regulation of hepatic lipid metabolism
Donald B. Jump
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2011)
Relationships between Plasma Fatty Acid Composition and Coronary Artery Disease
Hiroshige Itakura et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2011)
Omega-3 Fatty Acids and Cardiovascular Disease Effects on Risk Factors, Molecular Pathways, and Clinical Events
Dariush Mozaffarian et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Nuclear receptors and hepatic lipidogenic enzyme response to a dyslipidemic sucrose-rich diet and its reversal by fish oil n-3 polyunsaturated fatty acids
Gustavo J. Hein et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Antiobesity Effect of Eicosapentaenoic Acid in High-Fat/High-Sucrose Diet Induced Obesity Importance of Hepatic Lipogenesis
Ayumi Sato et al.
DIABETES (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dietary α-Linolenic Acid, EPA, and DHA Have Differential Effects on LDL Fatty Acid Composition but Similar Effects on Serum Lipid Profiles in Normolipidemic Humans
Sarah Egert et al.
JOURNAL OF NUTRITION (2009)
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
Yasushi Saito et al.
ATHEROSCLEROSIS (2008)
Differences between Dietary Supplement and Prescription Drug Omega-3 Fatty Acid Formulations: A Legislative and Regulatory Perspective
Nancy Collins et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2008)
Triglycerides and the risk of coronary heart disease - 10 158 incident cases among 262 525 participants in 29 Western prospective studies
Nadeem Sarwar et al.
CIRCULATION (2007)
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis
Mitsuhiro Yokoyama et al.
LANCET (2007)
Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids
Michael H. Davidson
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Why do omega-3 fatty acids lower serum triglycerides?
William S. Harris et al.
CURRENT OPINION IN LIPIDOLOGY (2006)
Effects of alpha-linolenic acid versus those of EPA/DHA on cardiovascular risk markers in healthy elderly subjects
P. L. L. Goyens et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2006)
n-3 fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies:: a systematic review
Chenchen Wang et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men
D Faeh et al.
DIABETES (2005)
分享论文
